# Harold J. Burstein

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/harold-j-burstein/

## Facts

| Field | Value |
| --- | --- |
| Citations | 50,939 |
| Field | Breast Cancer Treatment Studies |
| h-index | 102 |
| i10-index | 239 |
| Last Known Institution | Harvard University |
| OpenAlex ID | https://openalex.org/A5055301443 |
| ORCID iD | https://orcid.org/0000-0003-1963-8162 |
| Works | 441 |

## Researcher papers

- [Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013](https://scholariq.org/papers/personalizing-the-treatment-of-women-with-early-breast-cancer-highlights-of-the/)
- [American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer](https://scholariq.org/papers/american-society-of-clinical-oncology-guideline-recommendations-for-sentinel/)
- [Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/breast-cancer-version-3-2020-nccn-clinical-practice-guidelines-in-oncology/)
- [De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017](https://scholariq.org/papers/de-escalating-and-escalating-treatments-for-early-stage-breast-cancer-the-st/)
- [Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update](https://scholariq.org/papers/sentinel-lymph-node-biopsy-for-patients-with-early-stage-breast-cancer-american/)
- [Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/breast-cancer-version-3-2022-nccn-clinical-practice-guidelines-in-oncology/)
- [Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/early-breast-cancer-esmo-clinical-practice-guideline-for-diagnosis-treatment-and/)
- [Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer](https://scholariq.org/papers/adjuvant-paclitaxel-and-trastuzumab-for-node-negative-her2-positive-breast/)
- [Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline](https://scholariq.org/papers/endocrine-therapy-for-hormone-receptor-positive-metastatic-breast-cancer/)
- [Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/breast-cancer-version-3-2024-nccn-clinical-practice-guidelines-in-oncology/)
- [NCCN Guidelines® Insights: Breast Cancer, Version 4.2023](https://scholariq.org/papers/nccn-guidelines-insights-breast-cancer-version-4-2023/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)

## Researcher university

- [Harvard University](https://scholariq.org/institutions/harvard-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.